Catalent, Inc. (NYSE:CTLT) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 4.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,024,240 shares of the company's stock after acquiring an additional 45,564 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.56% of Catalent worth $62,038,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Millennium Management LLC lifted its holdings in shares of Catalent by 129.2% in the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company's stock worth $229,416,000 after purchasing an additional 2,299,784 shares in the last quarter. Bank of Montreal Can increased its holdings in Catalent by 181.5% during the 3rd quarter. Bank of Montreal Can now owns 1,813,167 shares of the company's stock worth $109,388,000 after purchasing an additional 1,169,044 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Catalent by 166.5% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company's stock worth $83,733,000 after purchasing an additional 863,624 shares during the last quarter. ING Groep NV lifted its holdings in shares of Catalent by 162.5% in the third quarter. ING Groep NV now owns 1,130,504 shares of the company's stock valued at $68,475,000 after purchasing an additional 699,851 shares in the last quarter. Finally, Mizuho Markets Americas LLC bought a new stake in Catalent during the third quarter worth $30,285,000.

Insider Buying and Selling

In related news, Director Michelle R. Ryan sold 2,800 shares of the business's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider David Mcerlane sold 1,994 shares of the company's stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,114 shares of company stock worth $305,931. Company insiders own 0.31% of the company's stock.

Analysts Set New Price Targets

CTLT has been the subject of several research analyst reports. StockNews.com upgraded shares of Catalent from a "sell" rating to a "hold" rating in a research report on Monday. Baird R W cut shares of Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. William Blair reaffirmed a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Robert W. Baird reiterated a "neutral" rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Eight analysts have rated the stock with a hold rating, According to MarketBeat.com, Catalent currently has a consensus rating of "Hold" and a consensus price target of $63.40.

Catalent Stock Up 0.5 %

CTLT stock traded up $0.29 during midday trading on Tuesday, hitting $61.72. 4,220,956 shares of the stock traded hands, compared to its average volume of 1,828,331. Catalent, Inc. has a 1-year low of $36.74 and a 1-year high of $62.08. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The stock's fifty day simple moving average is $59.93 and its 200-day simple moving average is $58.55.

Catalent (NYSE:CTLT - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business's quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.10) earnings per share. As a group, analysts anticipate that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.